39th Annual Miami Breast Cancer Conference® - Abstracts

15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients in a Breast Cancer Registry

May 6th 2022

37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device

BySteven C. Shivers,Pat W. Whitworth,Rachel Rabinovitch, MD,Frank Vicini, MD,Chirag Shah, MD,Fredrik Wärnberg,G. Bruce Mann,Karuna Mittal,Troy Bremer

May 6th 2022

18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19

ByMartine C. Maculaitis,Xianchen Liu,Alexandra Berk,Angelina Massa,Marisa C. Weiss,Samantha M. Kurosky,Benjamin Li,Lynn McRoy

May 6th 2022

43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy and Symptoms

ByAtilla Soran, MD, MPH,Fuat B. Bengur,Wendy Rodriguez,Efe Sezgin

May 6th 2022

3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer

ByGabriel Bandeira do Carmo,Monise Lazar,Suzana Ezquina,Guilherme Yamomoto,Thomaz Gollop,Mayana Zatz,Maria Passos-Bueno,Ana Krepischi,Oswaldo Keith Okamoto

May 6th 2022

44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center

ByHelene M. Sterbling,Ashish Chawla,Lolita Ramsey,Stephanie Akbari,David Weintritt,Shawna Willey, MD

May 6th 2022

39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy

BySteven C. Shivers,Pat W. Whitworth,Rakesh Patel,Troy Bremer,Charles E. Cox, MS, FACS

May 6th 2022

38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ

ByPat W. Whitworth,Rachel Rabinovitch, MD,Frank A. Vicini, MD,Chirag Shah, MD,Fredrik Wärnberg,G. Bruce Mann,Steven C. Shivers,Karuna Mittal,Troy Bremer

May 6th 2022

28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast

ByLindsay Miner,Allison M. Aripoli,Onalisa Winblad,Jessica Peterson,Marc Inciardi

May 6th 2022

20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study

ByMustafa Majid,Mohammed Mutar,Sara Sh. Ahmad,Enam Al-Tameemi

May 6th 2022

5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens

BySavitri Krishnamurthy,Payal Salgia,David Rempel,Andrew Berkeley,Beryl Augustine,Chandandeep Nagi,Alastair Thompson

May 6th 2022

41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast

ByCarolyn P. Smullin,Julie Le,Thomas E. Lawton,Jennifer L. Baker

May 6th 2022

45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction

ByMarisa C. Weiss,Adam Leitenberger,Frank J. Della Croce,Melissa Bollmann Jenkins,Donna-Marie Manasseh

May 6th 2022

29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients

ByVijayashree Murthy,Dana Borgen,Joshua Feinberg,Kristin E. Rojas,Vijaya Natarajan,Yocasta Mejia,Michael Silver,Charusheela Andaz,Donna-Marie Manasseh

May 6th 2022

36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?

ByDianne Seo,Catherine Carruthers,Kseniya Roudakova,Lina Sizer,Willian Carter,Thomas Frazier

May 6th 2022

17 Comparing Outcomes of Sequential vs Concurrent Breast and Gynecologic Risk Reduction Surgery

ByLila Lunt,Amanda Copeland,Margaret Schermerhorn,Andrea Madrigrano,Cristina O’ Donoghue,Melissa Rangel

May 6th 2022

16 Magseed Versus Wire Localisation: A Comparison

ByJessie Lenton,Emma Stewart-Parker,Nga Nguyen,Georgios Boustsikos,Nadine Betambeau,Dibyesh Banerjee,Anup Sharma,Sarah Tang

May 6th 2022

26 An Institution Wide Surgeon and Radiologist Survey of Savi Scout Versus Other Localization Procedure Preferences in Breast Conservation Surgery

ByKelly McGuigan,Allison Pensa,Stefania Nolano

May 6th 2022

21 TiP Pivotal Phase 3, Randomized Controlled Trial Evaluating the Safety and Efficacy of Aminolevulinic Acid for the Real-time Visualization of Cancer Through Fluorescent Imaging During Breast-Conserving Surgery

ByEleftherios P. Mamounas, MD, MPH,Rachel E. Eisenberg,Danielle Henry,Michael P. Kahky,Marisa P. Cooke,Jennifer Durant,Michael T. Roberts,Janice M. Porter,Amy Nester,Nayana Thalanki,Kathryn Ottolino-Perry,Ralph. S. DaCosta

April 19th 2022

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

ByEthan Sokol,Smruthy Sivakumar,Dexter X. Jin,Hanna Tukachinsky,Karthikeyan Murugesan,Dean Pavlick,Jeffrey S. Ross, MD,Garrett M. Frampton,Geoffrey R. Oxnard, MD,Priti S. Hegde

April 18th 2022

32 Impact of Comorbid HIV Infection on Breast Cancer Time to Treatment and Chemotherapy Relative Dose Intensity

ByElizabeth Rubin,Philippos Costa,Michael H. Antoni,Judith Hurley, MD,Gilberto Lopes, MD, MBA, FAMS,Danial S O’Neil

April 18th 2022

24 Real-world Use of Neratinib Post-Pertuzumab (P) and –Ado-Trastuzumab Emtansine (T-DM1)

ByKathryn Martin,Hope Rugo, MD,Gregory Vidal, MD, PhD,Nina Oestreicher,Deepa Lalla,Gillian Hanson,Daniel Drozd,Kristie Traverso,Dan DiPrimeo,Debu Tripathy, MD

April 18th 2022

19 Real-world Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Talazoparib-Treated Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer and Germline BRCA Mutations

ByReshma L. Mahtani, DO ,Jasmina Ivanova,Angelica Falkenstein,Alexander Niyazov,Joanne C. Ryan,Jonathan Kish,Ajeet Gajra,Kristin M. Zimmerman Savill

April 18th 2022

13 Assessing Intratumor Heterogeneity in Programmed Death-Ligand 1 (PD-L1) Protein Expression in Early-Stage Breast Cancer

ByAdriana Matutino Kahn,Reza Golestani,Malini Harigopal,Lajos Pusztai, MD, DPhil

April 18th 2022

2 Incidence, Clinical and Laboratory Predictors of Adverse Events (AEs) and Outcomes in Patients (Pts) With Breast Cancer Receiving Alpelisib in the Real World: A Single Institution Experience

BySabah Alaklabi,Arya Mariam Roy,Kristopher Attwood,Anthony George,Tracey O’Connor,Ellis G. Levine,Shipra Gandhi

April 18th 2022

6 Real-world Adherence and Persistence With Palbociclib Treatment Among Insured Patients With HR+/HER2– Metastatic Breast Cancer in the United States

ByNicole M. Engel-Nitz,Samantha M. Kurosky, Mary Grace Johnson,Michael P. Johnson,Xianchen Liu

April 18th 2022

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

ByAdam M. Brufsky, MD, PhD,Hannah M. Linden, MD,Hope S. Rugo, MD,Joyce A. O’Shaughnessy,Robert H. Getzenberg,K. Gary Barnette,Domingo Rodriguez,Mitchell Steiner,Erica L. Mayer, MD, MPH

April 18th 2022

8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination Therapy

ByElgene Lim, MBBS, FRACP, PhD,Adam M. Brufsky, MD, PhD,Hope S. Rugo, MD,Charles L. Vogel, MD, FACP,Joyce A. O’Shaughnessy,Robert H. Getzenberg,K. Gary Barnette,Domingo Rodriguez,Mitchell Steiner,Hannah M. Linden, MD

April 18th 2022

9 Real-world Treatment Patterns and Clinical Outcomes in Patients Treated With Eribulin After Prior Immunotherapy (IO) or Antibody-Drug Conjugate (ADC) for Metastatic Breast Cancer

ByRavi K. Goyal,Jingchuan Zhang,Samina Dhuliawala,Martina Sluga-O’Callaghan,Peter A. Kaufman, MD

April 18th 2022

39th Annual Miami Breast Cancer Conference® - Abstracts

15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients in a Breast Cancer Registry

37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device

18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19

43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy and Symptoms

3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer

44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center

39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy

38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ

28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast

20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study

5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens

41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast

45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction

29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients

36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?

17 Comparing Outcomes of Sequential vs Concurrent Breast and Gynecologic Risk Reduction Surgery

16 Magseed Versus Wire Localisation: A Comparison

26 An Institution Wide Surgeon and Radiologist Survey of Savi Scout Versus Other Localization Procedure Preferences in Breast Conservation Surgery

21 TiP Pivotal Phase 3, Randomized Controlled Trial Evaluating the Safety and Efficacy of Aminolevulinic Acid for the Real-time Visualization of Cancer Through Fluorescent Imaging During Breast-Conserving Surgery

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

32 Impact of Comorbid HIV Infection on Breast Cancer Time to Treatment and Chemotherapy Relative Dose Intensity

24 Real-world Use of Neratinib Post-Pertuzumab (P) and –Ado-Trastuzumab Emtansine (T-DM1)

19 Real-world Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Talazoparib-Treated Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer and Germline BRCA Mutations

13 Assessing Intratumor Heterogeneity in Programmed Death-Ligand 1 (PD-L1) Protein Expression in Early-Stage Breast Cancer

2 Incidence, Clinical and Laboratory Predictors of Adverse Events (AEs) and Outcomes in Patients (Pts) With Breast Cancer Receiving Alpelisib in the Real World: A Single Institution Experience

6 Real-world Adherence and Persistence With Palbociclib Treatment Among Insured Patients With HR+/HER2– Metastatic Breast Cancer in the United States

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

9 Real-world Treatment Patterns and Clinical Outcomes in Patients Treated With Eribulin After Prior Immunotherapy (IO) or Antibody-Drug Conjugate (ADC) for Metastatic Breast Cancer

Trending on CancerNetwork

H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice

Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC

177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC

FDA Grants Iopofosine I 131 Rare Pediatric Drug Designation in R/R Glioma

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC